ID
29550
Beschrijving
Study ID: 102932 Clinical Study ID: HZA102932 Study Title:An open-label, randomised, 3-way crossover single dose study to demonstrate dose proportionality of fluticasone furoate (FF) and equivalence of vilanterol (VI) when administered as FF/VI inhalation powder from the novel dry powder inhaler in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01213849 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Allermist,Veramyst,Avamys; Veramyst,Avamys,Allermist Study Indication: Asthma Documentation part: LOGS and Repeats
Trefwoorden
Versies (2)
- 10-03-18 10-03-18 -
- 05-04-18 05-04-18 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
5 april 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
GSK Dose proportionality of fluticasone furoate and equivalence of vilanterol in healthy adults NCT01213849
Similar models
LOGS and Repeats
- StudyEvent: ODM
C0877248 (UMLS CUI-2)
C0008976 (UMLS CUI-3)
C1320722 (UMLS CUI-4)
C0018941 (UMLS CUI [1,2])
C0200345 (UMLS CUI [1,3])
C0200345 (UMLS CUI [1,2])
C0031327 (UMLS CUI [1,2])
C0008000 (UMLS CUI [1,2])
C0587081 (UMLS CUI [1,3])